Kahn Swick & Foti, LLC has initiated a securities fraud class action lawsuit against uniQure N.V., alleging the biopharmaceutical company failed to disclose material information regarding its drug candidate AMT-130 prior to a significant stock decline. The company's shares fell 49% following the FDA's rejection of data supporting the drug's accelerated approval pathway, a development that the plaintiffs contend should have been communicated to investors earlier.
The lawsuit is part of a broader wave of securities litigation filed by the firm against multiple companies, including Corcept Therapeutics and BellRing Brands, which experienced substantial stock declines tied to FDA approval setbacks and operational challenges. These cases represent investor claims that the companies withheld or inadequately disclosed information that would have materially affected investment decisions.
Investors who purchased uniQure securities during the relevant period have until April 13, 2026 to submit lead plaintiff applications. The firm is accepting inquiries from affected shareholders regarding their potential participation in the litigation.